

University of Groningen

Prenatal exposure to antidepressants or antipsychotics and the risk of seizure in children

Wang, Zixuan; Chan, Adrienne Y L; Ho, Phoebe W H; Wong, Kirstie H T W; Brauer, Ruth; Besag, Frank M C; Ip, Patrick; Howard, Louise M; Lau, Wallis C Y; Taxis, Katja

Published in:
World psychiatry

DOI:
[10.1002/wps.20948](https://doi.org/10.1002/wps.20948)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2022

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Wang, Z., Chan, A. Y. L., Ho, P. W. H., Wong, K. H. T. W., Brauer, R., Besag, F. M. C., Ip, P., Howard, L. M., Lau, W. C. Y., Taxis, K., Wei, L., Wong, I. C. K., & Man, K. K. C. (2022). Prenatal exposure to antidepressants or antipsychotics and the risk of seizure in children. *World psychiatry*, *21*(2), 322-323. <https://doi.org/10.1002/wps.20948>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Prenatal exposure to antidepressants or antipsychotics and the risk of seizure in children

Perinatal mental health problems account for a substantial health burden across the world. Almost one in two women aged under 25 report some form of common mental disorders during pregnancy¹. The use of psychotropic medications, especially antidepressants and antipsychotics, has doubled in the past two decades, with a disproportionate increase amongst women at childbearing age and during pregnancy^{2,3}.

Despite increased prescribing, there is insufficient evidence supporting the safety of psychotropic drug use during pregnancy¹, in particular regarding seizure in offspring, one of the most common neurological conditions in early childhood and an important predictor of mortality, long-term disability, and poor prognosis⁴. This may lead to hesitations in perinatal psychiatric treatment: indeed, high rates of discontinuation of psychotropic medications have been observed in pregnant women with mental disorders^{5,6}. There can be significant adverse effects to both maternal and foetal health when stopping medications abruptly or withholding treatment during pregnancy^{5,6}.

We used the Hong Kong Clinical Data Analysis and Reporting System (CDARS)⁷ to examine the risk of seizure in offspring (ICD-9-CM diagnosis codes 333, 345, 779 and 780, with the exception of febrile convulsion, ICD-9-CM codes 780.31 and 780.32) associated with prenatal exposure to an antidepressant (British National Formulary, BNF chapter 4.3) or an antipsychotic medication (BNF chapter 4.2.1). We included all pregnant women aged 15-50 years who delivered a live birth between January 1, 2001 and December 31, 2015. All children had at least one-year follow-up by the end of the study period (December 31, 2016). Children without valid mother-child linkage or with incomplete birth information were excluded.

Children were considered as exposed prenatally if their mothers received any antidepressant or antipsychotic medication during the pregnancy period (“maternal gestational use”). Separate exposure cohorts were created for antidepressant and antipsychotic use. Mothers with epilepsy or prenatal lithium treatment may have an increased risk of having a child with seizure⁸; we therefore excluded pregnant women who had a diagnosis of epilepsy, and those treated with lithium during pregnancy. We also excluded mothers with antipsychotic or antidepressant prescriptions in the analyses of antidepressants or antipsychotics, respectively. We restricted the analyses to mothers who received at least two prescriptions of interest.

Based on maternal antidepressant/antipsychotic use in different risk periods, we classified the children into three comparator groups: a) those whose mothers did not use antidepressants/antipsychotics during pregnancy (“maternal gestational non-use”); b) those whose mothers used these drugs any time before pregnancy but stopped treatment when pregnant (“maternal past use”); and c) those whose mothers had never used the drugs before and during pregnancy (“maternal non-use ever”), who were

further classified into those with and without maternal psychiatric disorders (ICD-9-CM codes 290-319).

To explore the impact of confounding by indication, we compared children with “maternal past use” to those with “maternal non-use ever”. An increased risk of seizure among children with “maternal past use” indicates confounding by indication, as the infant was not exposed to antidepressants/antipsychotics. Similarly, children with “maternal gestational use” were compared to children with “maternal past use”. Secondly, to evaluate the role of maternal psychiatric disorders, we restricted comparison cohorts to children with “maternal non-use ever”.

Sibling-matched analysis was conducted to control for shared genetic and social confounding at the family level. Covariates for confounding adjustment were maternal age at delivery, calendar year at delivery, birth hospital, infant gender, parity, maternal underlying medical conditions and socioeconomic status. Cox proportional hazard regression models with propensity score fine-stratification weighting⁹ was used to estimate the hazard ratios with a 95% confidence interval (CI) to assess the association.

This study included 412,796 and 410,587 pairs of mother-child records in the antidepressant and antipsychotic analyses, with a mean follow-up time of 6.59±3.91 and 6.60±3.91 years, respectively. For antidepressants, the proportion of children diagnosed with seizure among those with “maternal gestational use” and “maternal gestational non-use” was 6.75% and 4.46%, respectively. For antipsychotics, the corresponding figures were 9.31% and 4.46%.

Thus, the prenatal use of antidepressants and antipsychotics was associated, respectively, with a 23% (propensity score weighted hazard ratio, wHR=1.23, 95% CI: 1.02-1.48) and 49% (wHR=1.49, 95% CI: 1.11-1.99) increased risk of seizure in children, when compared with unexposed children. However, the increased risk was not observed when children with “maternal gestational use” were compared to those with “maternal past use” (wHR=1.01, 95% CI: 0.79-1.28 for antidepressants; wHR=0.98, 95% CI: 0.64-1.50 for antipsychotics), as well as to those with “maternal non-use ever” and maternal psychiatric disorder (wHR=1.13, 95% CI: 0.88-1.44 for antidepressants; wHR=1.32, 95% CI: 0.93-1.89 for antipsychotics).

Moreover, when the analyses were restricted to children with “maternal non-use ever” of antidepressants or antipsychotics, the risk of seizure was consistently higher in children whose mothers had a psychiatric disorder, compared to those whose mothers had no psychiatric disorder (wHR=1.44, 95% CI: 1.25-1.67 for antidepressants; wHR=1.41, 95% CI: 1.20-1.66 for antipsychotics). Comparisons between children with “maternal gestational use” and the sibling-matched children with “maternal gestational non-use” also showed no statistically significant difference (wHR=1.16, 95% CI: 0.75-1.77 for antidepressants; wHR=1.19, 95% CI: 0.29-4.82 for antipsychotics).

The results of our study, therefore, do not support a causal

relationship between prenatal exposure to antidepressants or antipsychotics and the risk of seizure in children.

Since the first report of a possible association between psychotropic drug exposure *in utero* and childhood neurological disorders, clinicians have faced a dilemma regarding the management of women with mental disorders during both the time that they are trying to conceive and pregnancy. Ongoing efforts have been made to enhance perinatal psychiatric drug management, such as the European regulatory ban of valproate use in women of childbearing potential due to clear evidence of teratogenic and neurodevelopmental harm. However, current guidance on gestational antidepressant and antipsychotic use remains unclear due to the lack of strong clinical evidence.

When generating evidence, methodological considerations such as adequate adjustment for known confounders and increase in precision of estimates should be considered wherever possible, to minimize uncertainties of the results. Sustained efforts in ascertaining the specific benefits and harms of prenatal psychotropic medication exposure are pivotal towards individualized risk-benefit analyses of psychiatric treatment to safeguard both maternal and foetal health.

We cannot completely exclude the possibility that prenatal exposure to antidepressants or antipsychotics is related to risk for childhood seizure, but our study suggests that the association might be explained by confounding factors. Further studies stratifying antidepressants/antipsychotics by different drug classes,

exposure time in different trimesters, and first-time seizure diagnosed at different developmental timepoints are needed.

Zixuan Wang¹, Adrienne Y.L. Chan^{2,4}, Phoebe W.H. Ho², Kirstie H.T.W. Wong^{1,2}, Ruth Brauer¹, Frank M.C. Besag^{1,5}, Patrick Ip², Louise M. Howard⁶, Wallis C.Y. Lau^{1,2,4}, Katja Taxis³, Li Wei^{1,4}, Ian C.K. Wong^{1,2,4}, Kenneth K.C. Man^{1,2,4}

¹UCL School of Pharmacy, London, UK; ²University of Hong Kong, Hong Kong, China; ³University of Groningen, Groningen, The Netherlands; ⁴Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong, China; ⁵East London Foundation NHS Trust, Bedfordshire, UK; ⁶King's College London, London, UK

This study was supported by a Maplethorpe Fellowship. The authors are grateful to the Hong Kong Hospital Authority for access to the data from CDARS. The study protocol was approved by the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong West Cluster for CDARS database research. Z. Wang and A.Y.L. Chan are joint first authors, and I.C.K. Wong and K.K.C. Man are joint senior authors of the paper.

1. Howard LM, Khalifeh H. *World Psychiatry* 2020;19:313-27.
2. Reutfors JCC, Cohen JM, Bateman BT et al. *Schizophr Res* 2020;220:106-15.
3. Cooper WO, Willy ME, Pont SJ et al. *Am J Obstet Gynecol* 2007;196:544.e1-5.
4. Ronen GM, Buckley D, Penney S et al. *Neurology* 2007;69:1816-22.
5. Petersen I, Gilbert RE, Evans SJ et al. *J Clin Psychiatry* 2011;72:979-85.
6. Petersen I, McCrear RL, Osborn DJ et al. *Schizophr Res* 2014;159:218-25.
7. Hong Kong Hospital Authority. Caring for our community's health. <http://www.ha.org.hk>.
8. El Marroun H, White T, Verhulst FC et al. *Eur Child Adolesc Psychiatry* 2014;23:973-92.
9. Man KK, Chan EW, Ip P et al. *BMJ* 2017;357:j2350.

DOI:10.1002/wps.20948

Prevention, treatment and care of substance use disorders in times of COVID-19

Since 2015, the United Nations Office on Drugs and Crime (UNODC) – World Health Organization (WHO) Informal Scientific Network (ISN) has brought the voice of science to international drug policy discussions, especially at the Commission on Narcotic Drugs, the prime policy-making body of the United Nations (UN) for drug control matters. In recent years, the public health dimensions of the world drug problem, including prevention and treatment of substance use disorders (SUDs), have become prominent in policy debates within the UN system¹.

Individuals with SUDs are at increased risk of contracting COVID-19 and, if infected, are more likely to experience negative outcomes²⁻⁴. This vulnerability reflects both the adverse effects of the non-medical use of psychoactive substances on health⁵, compounded by high rates of non-attended medical comorbidities^{3,4}, as well as associated psychosocial and structural factors. These may include situations of homelessness and incarceration, which increase the risk of acquiring COVID-19 through intermediate and direct factors (e.g., poverty, stigma, overcrowded settings) and decrease access to adequate care, ultimately worsening outcomes⁶. Several surveys have identified disruptions of services for people with SUDs during the COVID-19 pandemic⁷. Providing services for population groups with increased vulner-

abilities is a key public health principle especially during a pandemic, also benefitting the general population as a whole⁴.

Evidence-based and human rights-based treatment of SUDs, including mental health and physical comorbidities, should be considered essential and integrated into existing health care services. The provision of remote services and digital health solutions for the treatment and care of SUDs, and medications to treat SUD and prevent overdose, should be accessible to those in need. Due to overlapping vulnerabilities, people who use substances with special treatment and care needs carry a disproportionate risk and require special attention⁸. Investment in evidence-based prevention and treatment of SUDs and comorbid health conditions, and attention to the impact of social determinants on the health of all age groups are now more necessary than ever. Global actions are needed to build health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond⁹.

The ISN shares the following recommendations in its 2021 statement:

- Support the timely collection and analysis of data to monitor the impact of the COVID-19 pandemic, including the role of